Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

Naloxone + oxycodone prolonged release tablets vs oxycodone

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Naloxone + oxycodone prolonged release tablets vs oxycodone

Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Naloxone + oxycodone prolonged release tablets vs oxycodone

Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 212 participants
Low

Naloxone + oxycodone prolonged release tablets vs oxycodone

Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

Naloxone + oxycodone prolonged release tablets showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with oxycodone prolonged‐released tablets (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 133 participants
Low

Naloxone + oxycodone prolonged release tablets vs oxycodone

Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.68 [0.44, 1.06]
3 studies · 362 participants
Very low

Naloxone + oxycodone prolonged release tablets vs oxycodone

Adverse events · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction

Naloxone + oxycodone prolonged release tablets showed no clear difference in adverse events compared with oxycodone prolonged‐released tablets (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 1.01 [0.87, 1.18]
3 studies · 362 participants
Low